about
Down syndrome and leukemia: insights into leukemogenesis and translational targetsTranscription factor GATA-1 and Down syndrome leukemogenesisEffect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status.The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy numberMethotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathologyMyelosuppression and infectious complications in children with Down syndrome and acute lymphoblastic leukemia.The use of mouse models for understanding the biology of down syndrome and agingDifferential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.Optimizing therapy for myeloid disorders of Down syndrome.Advances in paediatric cancer treatmentDown syndrome and acute lymphoblastic leukaemia.Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.Haematology of Down syndromeOutcome of transplantation for acute myelogenous leukemia in children with Down syndrome.Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia.Malignancy in children with trisomy 21.Unique clinical and biological features of leukemia in Down syndrome children.Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia.Acute lymphoblastic leukaemia in children with Down syndrome: an updated review.Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report.Immunosuppressive therapy for patients with Down syndrome and idiopathic aplastic anemia.Pulmonary hemosiderosis in children with Down syndrome: a national experience.Myelopathy mimicking subacute combined degeneration in a Down syndrome patient with methotrexate treatment for B lymphoblastic leukemia: report of an autopsy case.Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group.
P2860
Q26770335-EA559BBC-F0BA-4F3F-8DCE-48E885E0D612Q28251869-F9D484E3-3DD0-4982-9FE4-ED661C6755DEQ33525022-CC6F8940-A1FB-4E97-B690-2E1F45AF4D3AQ33931844-14A68262-5B14-4958-B628-985AB969F018Q33952766-8C372D6F-9ED0-4B22-A89B-9FEE5BBD87D6Q34611232-319DEB1E-4476-45A2-9828-D615A55B21D6Q35757411-B45B596E-EF51-4A15-9F5E-6CC168E5BDE8Q35810481-E1A9CA25-E0EA-4622-8E05-8C799D197A53Q35848677-C541A1D3-FD3A-4BB2-BE1E-23B82AE3D15CQ36246359-F0BA1E42-81C8-49AE-ACAD-957789C4C1F3Q36262215-DB4268EF-F063-4777-9A3E-505EA0ECA4A7Q36508630-2FD046DF-3F65-45BC-B41A-EB31921D0E40Q36630103-21C5B714-27C2-46A3-97AB-88BD4655EEDDQ36828315-A55E0F24-9D0C-43B3-94A7-BC1861576F68Q36931357-392C876E-E38C-44B2-BE3A-B23171A47A4CQ37000896-4389F159-0D88-48BE-803A-9F4DB94FD3F2Q37087261-6A3E8C08-967B-4DF6-BD94-4CB5AA1CDAECQ37379570-C0326FFA-4E09-4BF5-8CDC-DEAD2FE710EBQ37810271-D47480A7-C6B9-40BB-AFF9-BFFD71DC220BQ37929894-5E230D3A-C1E0-4BC4-9EB3-65EDBCF92ED6Q37935867-55E15C00-DEE5-43C6-82B1-00674097C1B0Q38733360-DCD012D5-5F36-4371-A0A3-C9017BA2336AQ42176458-72842F4A-50F6-4EFA-84C5-90A8499D3ED8Q46158135-EFF73016-4DD1-484E-93FE-56BD01605682Q50243275-C8438046-95CE-4552-BA75-E9681416AE8AQ52314065-66CAD373-B26E-4709-8A9A-BB01D53CC5A6Q53060966-C749D27A-CA16-4A6E-8B2A-43D7817F60A2Q53270825-0D6A2836-1409-40EC-AB2D-855C32550DCE
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Down syndrome, drug metabolism and chromosome 21.
@ast
Down syndrome, drug metabolism and chromosome 21.
@en
type
label
Down syndrome, drug metabolism and chromosome 21.
@ast
Down syndrome, drug metabolism and chromosome 21.
@en
prefLabel
Down syndrome, drug metabolism and chromosome 21.
@ast
Down syndrome, drug metabolism and chromosome 21.
@en
P356
P1476
Down syndrome, drug metabolism and chromosome 21.
@en
P2093
Jeffrey W Taub
P356
10.1002/PBC.20092
P577
2005-01-01T00:00:00Z